Arrowhead Pharmaceuticals Corp (ARWR) Reports In-Line Q3 EPS, Revenues Beat
Tweet
Share
E-mailGet Alerts ARWR Hot Sheet
Price: $81.51 +1.25%
EPS Growth %: +4.8%
Financial Fact:
Change in value of derivatives: -113.36K
Today's EPS Names:
FOMI, FLES, IMMR, More
EPS Growth %: +4.8%
Financial Fact:
Change in value of derivatives: -113.36K
Today's EPS Names:
FOMI, FLES, IMMR, More
Join SI Premium – FREE
Arrowhead Pharmaceuticals Corp (NASDAQ: ARWR) reported Q3 EPS of ($0.18), in-line with the analyst estimate of ($0.18). Revenue for the quarter came in at $727.38 thousand versus the consensus estimate of $690 thousand.
For earnings history and earnings-related data on Arrowhead Pharmaceuticals Corp (ARWR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- NVIDIA stock gains as SemiAnalysis sees H2 data center revenue 20% above consensus
- Alcoa agrees to buy South32 assets for $4.1 billion
- Jefferies Upgrades Murphy USA (MUSA) to Buy
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
